Literature DB >> 3377615

Physician practices in the treatment of pulmonary embolism and deep venous thrombosis.

A P Wheeler1, R D Jaquiss, J H Newman.   

Abstract

To quantify physician practices in the care of patients with presumed pulmonary embolism or deep venous thrombosis, we analyzed heparin sodium orders, the intensity of anticoagulation, and complications in 65 patients with the diagnosis of deep venous thrombosis or pulmonary embolism. All patients were given heparin, for a mean (+/- SEM) period of 8.8 +/- 0.4 days. A high percentage of patients (60%) did not have a single partial thromboplastin time (PTT) greater than 1.5 times control within the first 24 hours of heparin therapy. Not until day 8 were 90% of PTTs in therapeutic range. We identified five common practices that led to delays in achieving a PTT greater than 1.5 times the laboratory control: (1) failure to start heparin therapy at the time of initial clinical suspicion, (2) choice of a heparin sodium bolus (mean, 5861 +/- 365 U) and continuous infusion (1026 +/- 148 U/h) insufficient to elevate the PTT to greater than 1.5 times control, (3) delay in obtaining the first PTT (mean, 11.7 +/- 1 h after start of heparin therapy), (4) insufficient heparin dosing in response to a low PTT, and (5) excessive and prolonged reductions in heparin therapy in response to a PTT greater than three times control, leading to subtherapeutic levels in 56% of subsequent PTTs. We think that poor understanding of heparin kinetics, overcautious behavior of physicians, and high heparin requirements in this selected population account for the findings.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377615

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

1.  Hospital-based approach to the management of venous thromboembolism.

Authors:  F A Anderson
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  The pulmonary physician and critical care. 5. Management of pulmonary embolism.

Authors:  H H Gray; S Firoozan
Journal:  Thorax       Date:  1992-10       Impact factor: 9.139

Review 3.  Recognition and treatment of unstable angina.

Authors:  C Brunelli; P Spallarossa; P Rossettin; S Caponnetto
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

4.  Free-floating deep venous thrombosis. A retrospective analysis.

Authors:  R E Berry; J E George; W A Shaver
Journal:  Ann Surg       Date:  1990-06       Impact factor: 12.969

Review 5.  Intravenous heparin dosing: patterns and variations in internists' practices.

Authors:  B M Reilly; R Raschke; S Srinivas; T Nieman
Journal:  J Gen Intern Med       Date:  1993-10       Impact factor: 5.128

6.  Dosing of unfractionated heparin in obese patients with venous thromboembolism.

Authors:  Adam N Hurewitz; Samar U Khan; Maritza L Groth; Patricia A Patrick; Donald A Brand
Journal:  J Gen Intern Med       Date:  2010-12-15       Impact factor: 5.128

Review 7.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 8.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 9.  Prevention and treatment of venous thromboembolism.

Authors:  G F Pineo; R D Hull
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

10.  Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study.

Authors:  Faisal Alsayegh; Mona Al-Rasheed; Ali Al-Muhaini; Ekhlas Al-Humoud; Mona Al-Ostaz; Shaker A Mousa
Journal:  Cardiovasc Ther       Date:  2009       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.